Skip to main content
Category

News Archive

nhlbi-logo-new.png

February Funding Deadlines in Cystic Fibrosis, Microfluidic Platforms, and Stem Cell-Derived Blood Product Technologies

By News Archive

nhlbi-logo-new.png

The National Heart, Lung, and Blood Institute (NHLBI) has 3 targeted funding opportunities with deadlines in February. It’s also not too early to start preparing for the April 5 Omnibus solicitation deadline. Check your registrations (SAM must be renewed annually!) and reach out to discuss your project.

For questions about the NHLBI SBIR/STTR programs, contact Small Business Coordinator Jennifer Shieh, PhD at NHLBI_SBIR@mail.nih.gov

Human Cellular Models for Predicting Individual Responses to CFTR-Directed Therapeutics— Due February 9

For the development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis lung disease.

SBIR:
RFA-HL-15-027 STTR: RFA-HL-15-026

For questions about these funding opportunities, contact:
Robert Smith, PhD, robert.smith4@nih.gov
Program Director, Division of Lung Diseases

Development of a Microfluidic Platform for Blood Testing in Neonatal & Pediatric Patients— Due February 10 (Phase II only)

For the development of microfluidic devices to analyze blood for factors related to the thrombotic, transfusion, and/or hemostatic status of pediatric/neonatal patients.

SBIR—Phase II only: RFA-HL-14-026
This application must be based on an awarded SBIR or STTR-funded Phase I project.

For questions about this funding opportunity, contact:
Ronald Warren, PhD, rwarren@nhlbi.nih.gov
Program Director, Division of Blood Diseases and Resources

Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement— Due February 20

For tools and technologies that enable further advances in the manufacturing process to produce safe and functional blood and platelet products at reduced costs.

SBIR: RFA-HL-15-030 STTR: RFA-HL-15-029

Slides from the January 8 webinar are available—please send a request to NHLBI_SBIR@mail.nih.gov.

For questions about these funding opportunities, contact:
Shimian Zou, PhD, shimian.zou@nih.gov
Program Director, Division of Blood Diseases and Resources

John Thomas, PhD, thomasj@nhlbi.nih.gov
Program Director, Division of Blood Diseases and Resources

startup-maryland-logo-white

Startup Maryland Announces Shahab Kaviani as Entrepreneur-in-Residence

By News Archive

startup-maryland-logo-white

Startup Maryland (www.startupmd.org) today announced appointment of serial entrepreneur Shahab Kaviani as Entrepreneur-in-Residence (EiR).

A recognized leader of startup communities globally, Kaviani brings over a decade of first-hand entrepreneurial expertise and leadership experience most-recently as co-founder and CEO of Rockville, MD based CoFoundersLab (now Onevest). Previously, Kaviani served on the executive management team growing another Maryland company, HyperOffice, into a cloud-collaboration software leader.

Read More
pharmathene-logo

PharmAthene awarded $195M judgment in Siga case – Washington Business Journal

By News Archive

pharmathene-logo

PharmAthene Inc. now knows how much money it stands to get in its long-running lawsuit with Siga Technologies Inc.: A judge Thursday said Siga must pay PharmAthene $195 million and $30,663 per day in interest if Siga loses its appeal to the Delaware Supreme Court.

The case dates to 2006, when Annapolis-based PharmAthene sued New York-based Siga after the companies’ planned merger fell apart. PharmAthene claimed it was entitled to some of the profits from Tecovirimat, Siga’s smallpox antiviral.

Read More
iphone-mockup-rgbstock

How Technology Will Eat Medicine – Vivek Wadhwa

By News Archive

iphone-mockup-rgbstock

The most significant announcement that Apple made in 2014 wasn’t a larger-sized iPhone. It was that Apple is entering the health-care industry. With HealthKit, it is building an iTunes-like platform for health; Apple Watch is its first medical device. Apple is, however, two steps behind Google, IBM, and hundreds of startups. They realized much earlier that medicine is becoming an information technology and that the trillion-dollar health-care market is ripe for disruption.

Read More
alexandria-real-estate-logo

Real Estate Developer to Raise $20M to Build Digital Health Startups

By News Archive

alexandria-real-estate-logo

Alexandria Real Estate Equities, the largest owner and developer of real estate for the life-sciences industry in the nation wants to raise up to $20 million to build digital health startups in San Francisco, SFGate reports. Last year, the real estate developer announced that it would start three new accelerators nationwide to focused on agriculture, biotech and digital health. The biotech space is already up and running in New York City and has attracted giant pharma companies such as Pfizer Inc. and Eli Lily & Co with $51 million in funding. The agriculture space is scheduled to open later this year in North Carolina. 

Read More
britz-judy-biomaryland-image

Judy Britz is wrapping up five years of public service at the helm of the BioMaryland Center

By News Archive

britz-judy-biomaryland-image

Please join us in wishing her well as she embarks on retirement and new adventures.

When:

January 20, 2015 4:30 p.m. – 6:00 p.m. (Remarks at 5:15 p.m.) La Tasca – Baltimore – 201 East Pratt St. (Parking validated at 100 Pratt St.- $5) Cash bar; light horse d’euvres

and/or

January 28, 2015 4:00 p.m. – 5:00 p.m. (Remarks at 4:15 p.m.; BioBuzz networking ’til 7:30 p.m.) Growlers – Gaithersburg – 227 West Diamond St. Cash bar; light horse d’euvres

Read More
usa-map-usgs-public-domain

Venture Capital – Year in Review 2014 – CB Insights

By News Archive

usa-map-usgs-public-domain

Venture capital funding hit its highest annual mark since 2001 as venture investors participated in $47.3 billion across 3,617 deals. Even versus 2013, the past year was huge as venture capital skyrocketed 62% YoY due to multiple $500M+ mega-rounds while deal growth was more modest, climbing 8%. Of note, two quarters each – Q2’14 and Q4’14 – notched over $13B in funding.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.